Welcome to our dedicated page for Natera news (Ticker: $NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Natera's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Natera's position in the market.
Rhea-AI Summary
Natera, Inc. (NTRA) has won a patent infringement case against CareDx, Inc., with the jury awarding Natera $83.7 million in lost profits and $12.6 million in past royalties. The jury also found that all asserted claims of Natera's patents are valid and provided an advisory verdict that all asserted claims are valid under 35 U.S.C. Sec. 101. Further proceedings will determine whether CareDx's future sales of new versions of AlloSeq and AlloSure also infringe Natera's patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) has been found to have not infringed on Natera, Inc.'s patent 10,655,180 but was found to have infringed on patent 11,111,544. The District of Delaware jury awarded Natera damages of $83,679,521 in lost profits and $12,535,500 in past royalties for alleged infringement by AlloSure from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not impact patient or physician access to CareDx's current offerings, including AlloSure or AlloMap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced the publication of two new studies in Nature Medicine evaluating Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera.™ The first study, AMPLIFY-201, evaluated the ELI-002 cancer vaccine and enrolled 25 patients with solid tumors. Results showed that 21 patients had Signatera-positive status after locoregional treatment, and tumor biomarker responses were observed in 84% of patients. The study highlights the potential utility of ctDNA as a reliable surrogate biomarker for treatment efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
Rhea-AI Summary
Natera, Inc. (NTRA) has acquired certain assets from Invitae (NVTA) related to non-invasive prenatal screening and carrier screening business. The upfront payment to Invitae was $10 million, with potential milestone payments totaling $42.5 million. Invitae will transition its customers to Natera. Natera CEO, Steve Chapman, expressed commitment to providing excellent service and supporting additional patients and providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Invitae (NVTA) completes the sale of reproductive health assets to Natera (NTRA) for up to $52.5 million, aiming to focus on clinical germline genetic information and reduce operating expenses by approximately $44 million annually. Natera has hired Invitae reproductive health sales representatives and will take over customer transition for non-invasive prenatal and carrier screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to be presented at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium. The data includes updated 24-month DFS analysis from GALAXY and first interim analysis from BESPOKE CRC. Natera and its collaborators will present 11 abstracts featuring new Signatera data across various GI indications, including two oral presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced the jury's verdict in a patent infringement lawsuit brought by Ravgen, Inc. The damages award of $57 million was significantly less than the $410 million sought by Ravgen. The jury also determined there was no willful infringement by Natera. The patent at issue has expired, and Natera plans to file an appeal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.3%
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) expects total revenues of approximately $300 million in the fourth quarter of 2023, an increase of approximately 38% compared to $217 million in the fourth quarter of 2022. Total revenues of approximately $1.07 billion in 2023, an increase of approximately 30% compared to $820 million in 2022. These results demonstrate significant growth and surpass the top end of the company's revenue guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) to participate in the 42nd Annual J.P. Morgan Healthcare Conference. Management to deliver a presentation and host a Q&A with the investment community. Live webcast available on investor.natera.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
News
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) has announced that the federal District Court has issued a preliminary injunction against NeoGenomics, barring them from making, using, selling, or promoting their RaDaR molecular residual disease (MRD) assay in the United States, with limited exceptions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
Natera, Inc.
Nasdaq:NTRA
NTRA Rankings
NTRA Stock Data
13.18B
116.45M
4.1%
96.19%
5.17%
Medical Laboratories
Health Care and Social Assistance
United States of America
AUSTIN
About NTRA
natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the